Revised 21st Century Cures bill takes a step back on NIH research transparency

By Zachary Brennan contact

- Last updated on GMT

Revised 21st Century Cures bill takes a step back on NIH research transparency

Related tags: Clinical trial

With a House floor vote looming this week, legislators will decide on a revised bill that has decreased the amount of funding that will go to the NIH from the original bill, and removed a section that would have required NIH grant recipients to share scientific data.

When asked how these revisions will impact the NIH and the transparency of NIH-funded research, a spokeswoman told us that the agency does not comment on pending legislation. Currently, PIs (principal investigators) and funding recipient institutions are expected to make the results and accomplishments of their activities available to the research community and to the public at large.


The new bill would still increase NIH funding by about $8.75bn over the next five years, which compares with $10bn that the House Committee on Energy and Commerce unanimously passed in May​.

And provisions that might impact CROs (contract research organizations) -- such as the establishment of a national pediatric research network​, the standardization of inclusion and exclusion criteria across ClinicalTrials.Gov, or encouraging the use of master protocols to speed drug development – are still included in the bill.

Also included in the revised bill are new requirements for the FDA, particularly related to issuing new guidance that could eventually impact CROs, such as guidance assisting sponsors in incorporating adaptive designs and Bayesian statistical modeling into proposed clinical protocols and applications.

CBO Estimates

The revisions followed estimates from the Congressional Budget Office​ (CBO) last week that say implementing the bill would cost $106.4bn between 2016 and 2020, and would reduce direct spending, on net, by $11.9bn over the period of 2016 to 2025.

Advocates for the bill, however, say that entitlement changes will lead to billions in additional savings in Medicare and Medicaid in the second decade and beyond, which are not quantified by the CBO. House Energy and Commerce staff also calculated that the permanent entitlement reforms in 21st Century Cures will cut federal spending by an additional $7bn in the second decade following the act’s implementation.

Included in that cost of implementation would be $6m for the FDA to establish a pilot program to create a research sharing system, in coordination with NIH, which would give third parties direct access to data generated from government-funded clinical trials and would assist NIH with standardizing certain information related to eligibility for clinical trials.

House Majority Leader Kevin McCarthy (R-CA) said the House will consider the 21st Century Cures Act sometime later this week. The House Committee on Rules will meet to discuss the revised bill Wednesday while amendments to the legislation are expected to be filed by today.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more